USANA Health Sciences, Inc. (NYSE:USNA) Director Myron W. Wentz sold 5,688 shares of the firm’s stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $124.27, for a total value of $706,847.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of USNA stock traded down $0.15 during mid-day trading on Friday, hitting $124.60. 4,386 shares of the stock were exchanged, compared to its average volume of 128,237. The firm has a market cap of $3.05 billion, a price-to-earnings ratio of 30.74 and a beta of 0.64. USANA Health Sciences, Inc. has a 12-month low of $55.50 and a 12-month high of $137.95.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, July 24th. The company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.25. The company had revenue of $301.50 million for the quarter, compared to analyst estimates of $278.41 million. USANA Health Sciences had a return on equity of 29.50% and a net margin of 7.16%. The business’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.98 earnings per share. research analysts forecast that USANA Health Sciences, Inc. will post 4.9 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC grew its holdings in shares of USANA Health Sciences by 7.3% during the second quarter. Renaissance Technologies LLC now owns 2,105,466 shares of the company’s stock worth $242,760,000 after purchasing an additional 144,000 shares during the last quarter. BlackRock Inc. grew its holdings in shares of USANA Health Sciences by 16.0% during the second quarter. BlackRock Inc. now owns 962,366 shares of the company’s stock worth $110,961,000 after purchasing an additional 133,076 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of USANA Health Sciences during the second quarter worth about $103,349,000. Dimensional Fund Advisors LP grew its holdings in shares of USANA Health Sciences by 1.9% during the first quarter. Dimensional Fund Advisors LP now owns 777,313 shares of the company’s stock worth $66,771,000 after buying an additional 14,692 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of USANA Health Sciences by 121.4% during the second quarter. Millennium Management LLC now owns 186,974 shares of the company’s stock worth $21,558,000 after buying an additional 102,529 shares during the last quarter. 56.38% of the stock is currently owned by institutional investors.

Separately, Pivotal Research reaffirmed a “hold” rating and set a $135.00 price objective on shares of USANA Health Sciences in a report on Wednesday, July 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $135.00.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Further Reading: Marijuana Stocks Future Looks Bright

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.